SNDX - Syndax Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2019-12-31
2018-12-31
2017-12-31
2016-12-31
Total Revenue
1,517
1,517
1,517
2,108
1,220
Operating Expenses
Research Development
41,277
42,994
60,106
48,201
31,665
Selling General and Administrative
18,068
16,062
17,287
15,861
13,321
Total Operating Expenses
59,345
59,056
77,393
64,062
44,986
Operating Income or Loss
-57,828
-57,539
-75,876
-61,954
-43,766
Total Other Income/Expenses Net
-156
-79
-27
-269
-1,662
Income Before Tax
-56,981
-56,047
-73,961
-60,802
-44,472
Income from Continuing Operations
-56,981
-56,047
-73,961
-60,802
-44,472
Net Income
-56,981
-56,047
-73,961
-60,802
-44,472
Net Income available to common shareholders
-56,981
-56,047
-73,961
-60,802
-47,070
Basic EPS
-
-
-2.92
-2.90
-3.22
Diluted EPS
-
-
-2.92
-2.90
-3.22
Basic Average Shares
-
-
25,372
20,997
14,620
Diluted Average Shares
-
-
25,372
20,997
14,620
EBITDA
-
-57,447
-75,798
-61,878
-43,677